MBRX - Moleculin reports additional positive interim results in adult glioblastoma trial

Moleculin Biotech (MBRX) announces additional preliminary data from the Phase 1 clinical trial of its immuno-stimulating STAT3 inhibitor, WP1066, in patients with glioblastoma ((GBM)). This supports the progression of the trial to the fourth and final dose escalation cohort.Three patients have completed treatment in the third cohort at a dose level of 8 mg/kg with no adverse events and the study will now proceed to the next higher dose of 16 mg/kg. "The trial in adults has been important in leading the way to establishing a safe and tolerable human dose level for what we believe is a first-in-class compound that crosses the blood-brain barrier and is being developed for the treatment of central nervous system malignancies," stated Walter Klemp, Chairman and CEO.

For further details see:

Moleculin reports additional positive interim results in adult glioblastoma trial